• Ceftolozane/Tazobactam: Resistant Gram-Negative Infections

  2026-09-16

  The 2015 review of ceftolozane/tazobactam explains how a focused antipseudomonal cephalosporin paired with tazobactam addresses important resistance mechanisms in gram-negative pathogens. Its synthesis of mechanism, pharmacokinetics, pharmacodynamics, clinical evidence, and safety provides a practical framework for interpreting this combination in complicated intraabdominal and urinary tract infections.

• Polybrene: Mechanism and Workflow Guide

  2026-09-16

  Polybrene, also called Hexadimethrine Bromide, is a cationic polymer used to improve viral gene delivery and selected lipid-mediated DNA transfection workflows. The 10 mg/mL formulation supports reproducible handling, but exposure duration and cell-specific toxicity require empirical optimization.

• MLKL-Driven Lysosomal Permeabilization in Necroptosis

  2026-09-15

  The reference study identifies MLKL polymerization-induced lysosomal membrane permeabilization as a mechanistic link between necrosome activation and necroptotic cell death. Imaging, perturbation, and MLKL domain experiments place cathepsin B release downstream of lysosomal damage and show that this protease contributes substantially to cell killing.

• Cefoperazone: From β-Lactam Biology to Translation

  2026-09-15

  Cefoperazone sodium salt offers translational researchers a practical model for connecting β-lactamase stability, organism-specific antibacterial activity, assay design, and biliary distribution. This thought-leadership article places Cefoperazone within historical comparative data while outlining a more rigorous path from in vitro antimicrobial activity assay results to infection-model decisions.

• IPR-803: Urokinase Receptor Inhibitor Workflows

  2026-09-14

  IPR-803 is a mechanistically defined urokinase receptor inhibitor for testing uPAR–uPA biology in invasion, metastasis, angiogenesis, and tumor-stroma workflows. Its strongest value comes from pairing biochemical competition assays with orthogonal cell-based and pharmacokinetic measurements rather than treating reduced viability as the primary endpoint.

• ABT-199 (Venetoclax): Selective Bcl-2 Inhibitor

  2026-09-14

  ABT-199, also known as Venetoclax and GDC-0199, is a potent, selective BCL-2 inhibitor for mechanistic apoptosis research. Its reported selectivity over BCL-XL, BCL-w, and MCL-1 supports focused studies of the mitochondrial apoptosis pathway in hematologic malignancy models.

• Z-VDVAD-FMK: Mapping Apoptosis in NSCLC

  2026-09-13

  A translational guide to using Z-VDVAD-FMK to distinguish caspase-2-linked mitochondrial apoptosis from caspase-1-driven pyroptosis, with practical validation strategies for cancer research.

• LMO2–LDB1 Signaling in Acute Myeloid Leukemia

  2026-09-12

  The reference study identifies an LMO2/LDB1 protein complex as a functional driver of acute myeloid leukemia cell proliferation and survival. By combining protein-interaction analysis, genetic perturbation, transcriptomics, chromatin profiling, rescue experiments, and in vivo validation, it connects LDB1-dependent transcriptional regulation with AML maintenance and highlights a potentially actionable regulatory axis.

• Temafloxacin and Combination Activity Against M. avium

  2026-09-11

  The 1993 Journal of Antimicrobial Chemotherapy study evaluated clarithromycin, Temafloxacin, and ethambutol against 20 Mycobacterium avium complex strains using extracellular MIC/FIC testing and macrophage infection models. Its central finding was that combination activity was strain dependent, while the three-drug combination produced the strongest intracellular bactericidal effect, supporting phenotype-aware and compartment-specific antimicrobial testing.

• Polybrene: Practical Guide to Viral Transduction

  2026-09-11

  Polybrene (Hexadimethrine Bromide) improves viral attachment and uptake while also supporting difficult lipid-mediated DNA transfection workflows. This guide connects concentration screening, exposure control, and metabolic assay design to practical research use cases, including studies of the TCAIM–OGDH mitochondrial pathway.

• Hydrocortisone in EMT Splicing Assays

  2026-09-10

  Hydrocortisone is more than a glucocorticoid hormone supplement in cell culture. This guide explains how controlled hydrocortisone exposure should be interpreted when studying CLSTN1 splicing, EMT, and breast cancer metastasis.

• Polybrene Workflows for Transduction and Transfection

  2026-09-10

  Learn how Polybrene (Hexadimethrine Bromide) improves viral delivery and supports difficult DNA transfection without treating it as a one-size-fits-all additive. This practical guide also shows how controlled transduction workflows can support targeted protein-degradation assay development while preserving appropriate biological controls.

• Biotin-16-UTP for lncRNA Capture Assays

  2026-09-09

  Discover how Biotin-16-UTP supports biotin-labeled RNA synthesis, streptavidin-based capture, and mechanistic follow-up of lncRNA biomarkers such as RNASEH1-AS1. This guide connects integrative cancer biology with practical assay design, controls, and interpretation limits.

• Pexmetinib (ARRY-614) Workflow Guide

  2026-09-09

  Pexmetinib (ARRY-614) combines p38 MAPK and Tie2 pathway modulation for experiments that connect inflammatory cytokine inhibition with vascular and hematologic signaling. This practical guide covers assay setup, concentration selection, phospho-protein validation, and troubleshooting for more reproducible results.

• Relative and Fractional Viability in Cancer Drug Studies

  2026-09-08

  Schwartz’s 2022 dissertation distinguishes relative viability from fractional viability, showing that growth inhibition and cell death are related but not interchangeable drug-response outcomes. The framework supports better assay design, time-course interpretation, and mechanistic classification of anti-cancer compounds.

8147 records 1/544 page Next 12345 下5页 Last page